MedTrace Logo

N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms

NCT03221231 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2020-12-08

No results posted yet for this study

Summary

This study investigates the effects of repeated NAC administration on glutamate concentrations in the anterior cingulate cortex (ACC), on neurocognitive functioning, and on neuro-inflammatory parameters in adult cannabis-dependent individuals.

Conditions

  • Cannabis Use Disorder
  • Cannabis Dependence

Interventions

DRUG

N-acetylcysteine

1200 mg/day, twice daily, N-acetylcysteine

DRUG

Placebo Oral Tablet

twice daily, placebo

OTHER

Magnetic Resonance Imaging

OTHER

Neurocognitive measures

OTHER

Neuro-inflammatory measures

Sponsors & Collaborators

  • Universitair Ziekenhuis Brussel

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-15
Primary Completion
2022-02-01
Completion
2023-02-01

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03221231 on ClinicalTrials.gov